Abviva, Inc. Announces Patent Issuance for Core Technology Used in Mammastatin Serum Assay Diagnostic Test for Breast Cancer

Published: Feb 22, 2008

LOS ANGELES--(BUSINESS WIRE)--Abviva, Inc. (Abviva) (OTCBB:AVVA), a biomedical company engaged in the innovation, development and commercialization of breast cancer diagnostic and therapeutic applications of Mammastatin, announced today that the United States Patent and Trademark Office issued a pivotal patent on the core technology used in the Company’s breast cancer diagnostic test, the Mammastatin Serum Assay (MSA). The patent, titled METHODS AND COMPOSITION FOR DIAGNOSING BREAST CANCER is the most recent of the patents in the Mammastatin IP portfolio to issue to the University of Michigan for breast cancer diagnostic and breast cancer therapeutic uses. “Abviva is the exclusive licensee of the diagnostic uses for Mammastatin in the patent portfolio owned by the University of Michigan and licensed to Abviva,” said Doug Lane, president and chief executive of the company. “Abviva has the exclusive option to license the therapeutic uses of Mammastatin from the University of Michigan to develop one or more breast cancer therapeutic drugs.”

Back to news